Impact of 18F-fluciclovine PET/CT on Clinical Management of Patients with Recurrent Prostate Cancer: Results from the Phase 3 FALCON Trial

When biochemical recurrence (BCR) of prostate cancer is suspected, early and accurate localization of metastases facilitates treatment when tumors are small and most amenable to localized therapy, and may guide clinicians in making management plans regarding salvage therapy. Here, we present results of a preplanned analysis of the FALCON trial (NCT02578940), which assessed the impact of PET/CT imaging with 18F-fluciclovine on clinical management choices for men with BCR of prostate cancer.